Cancer Family
Peripheral Nervous System Neoplasm
CI-CAN-00000316Explore in graph →
Non-malignant71 active trials8 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000316Explore in graph →
Clinical trials
261 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT07407803 | Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas | recruiting | Phase 3 | 177 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY |
| 1 |
| May 27, 2026 |
| clinicaltrials |
| NCT04924608 | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas(KOMET) | active not recruiting | Phase 3 | 145 | AstraZenecaINDUSTRY | 13 | Mar 23, 2026 | clinicaltrials |
| NCT05913037 | FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | active not recruiting | Phase 3 | 167 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03176693 | Preoperative Alpha Blockade for Pheochromocytoma | completed | Phase 3 | 39 | University of California, Los AngelesOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT00346164 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | completed | Phase 3 | 588 | Children's Oncology GroupNETWORK | 5 | Apr 28, 2022 | clinicaltrials |
| NCT00126412 | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma | completed | Phase 3 | 251 | GE HealthcareINDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT00002641 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | completed | Phase 3 | 350 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 8, 2014 | clinicaltrials |
| NCT00427583 | Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | terminated | Phase 2 / Phase 3 | 11 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00002764 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | completed | Phase 3 | 340 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 11, 2012 | clinicaltrials |
| NCT01373736 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | unknown | Phase 3 | — | Vancouver Coastal HealthOTHER_GOV | 1 | Jun 15, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials